US Stock MarketDetailed Quotes

CERO CERo Therapeutics

Watchlist
  • 0.940
  • -0.050-5.04%
Close May 23 16:00 ET
  • 0.930
  • -0.010-1.06%
Post 18:14 ET
14.16MMarket Cap-1899P/E (TTM)

CERo Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q1)Mar 31, 2022
(FY)Dec 31, 2021
Total revenue
0
0
0
0
Operating revenue
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
-30.97%2.44M
3.06%11.97M
3.53M
11.62M
Selling and administrative expenses
-13.30%638.35K
-14.27%2.13M
--736.28K
--2.48M
-General and administrative expense
-13.30%638.35K
-14.27%2.13M
--736.28K
--2.48M
Research and development costs
-35.63%1.8M
7.76%9.85M
--2.8M
--9.14M
Operating profit
30.97%-2.44M
-3.06%-11.97M
-3.53M
-11.62M
Net non-operating interest income expense
-99.91%16
-85.60%142.12K
17.27K
986.71K
Non-operating interest income
-99.91%16
-85.60%142.12K
--17.27K
--986.71K
Other net income (expense)
Income before tax
30.64%-2.44M
-11.28%-11.83M
-3.52M
-10.63M
Income tax
Net income
30.64%-2.44M
-11.28%-11.83M
-3.52M
-10.63M
Net income continuous Operations
30.64%-2.44M
-11.28%-11.83M
---3.52M
---10.63M
Minority interest income
Net income attributable to the parent company
30.64%-2.44M
-11.28%-11.83M
-3.52M
-10.63M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
30.64%-2.44M
-11.28%-11.83M
-3.52M
-10.63M
Basic earnings per share
30.64%-0.2369
-11.28%-1.1493
-0.3415
-1.0327
Diluted earnings per share
30.64%-0.2369
-11.28%-1.1493
-0.3415
-1.0327
Dividend per share
Currency Unit
USD
USD
USD
USD
(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q1)Mar 31, 2022(FY)Dec 31, 2021
Total revenue 0000
Operating revenue --0--0--0--0
Cost of revenue
Gross profit
Operating expense -30.97%2.44M3.06%11.97M3.53M11.62M
Selling and administrative expenses -13.30%638.35K-14.27%2.13M--736.28K--2.48M
-General and administrative expense -13.30%638.35K-14.27%2.13M--736.28K--2.48M
Research and development costs -35.63%1.8M7.76%9.85M--2.8M--9.14M
Operating profit 30.97%-2.44M-3.06%-11.97M-3.53M-11.62M
Net non-operating interest income expense -99.91%16-85.60%142.12K17.27K986.71K
Non-operating interest income -99.91%16-85.60%142.12K--17.27K--986.71K
Other net income (expense)
Income before tax 30.64%-2.44M-11.28%-11.83M-3.52M-10.63M
Income tax
Net income 30.64%-2.44M-11.28%-11.83M-3.52M-10.63M
Net income continuous Operations 30.64%-2.44M-11.28%-11.83M---3.52M---10.63M
Minority interest income
Net income attributable to the parent company 30.64%-2.44M-11.28%-11.83M-3.52M-10.63M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 30.64%-2.44M-11.28%-11.83M-3.52M-10.63M
Basic earnings per share 30.64%-0.2369-11.28%-1.1493-0.3415-1.0327
Diluted earnings per share 30.64%-0.2369-11.28%-1.1493-0.3415-1.0327
Dividend per share
Currency Unit USDUSDUSDUSD

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg